 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Jason S. Lewis | |
|---|---|
| Born | February 1970 Liss, England |
| Education | BSc, University of Essex PhD, University of Kent |
| Occupation(s) | Radiochemist, professor |
| Scientific career | |
| Fields | Molecular Imaging, radiochemistry |
| Institutions | Washington University School of Medicine Memorial Sloan Kettering Cancer Center |
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality (PET, CT & MRI) small- and biomolecule-based agents and their clinical translation.[1] He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.[2]
- ^ "Professor Jason Lewis joins Clarity Pharmaceuticals' Advisory Board". Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging. 2018-10-11. Retrieved 2019-06-07.
- ^ Lewis, Jason S.; Evans, Michael J.; Fox, Ian L.; Caen, Jonathan D.; Dilling, Thomas R.; Dacek, Megan M.; Henry, Kelly E. (2019-01-01). "A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer". Clinical Cancer Research. 25 (1): 166–176. doi:10.1158/1078-0432.CCR-18-1485. ISSN 1078-0432. PMC 6320277. PMID 30228208.